Sugi Predict

Sugi Predict / Compounds / SCHEMBL1674765

SCHEMBL1674765

SCHEMBL1674765

CC(C)C[C@H](NC(=O)CNC(=O)[C@@H](N)CCCCN)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TERT O14746 1/20 0.50
▸ GNAI3 P08754 1/20 0.46
▸ GNAO1 P09471 1/20 0.46
▸ GNAI1 P63096 1/20 0.46
▸ ERAP2 Q6P179 1/20 0.45
▸ ERAP1 Q9NZ08 1/20 0.45
▸ LNPEP Q9UIQ6 1/20 0.45
▸ OPRD1 P41143 3/20 0.45
▸ OPRM1 P35372 2/20 0.45
▸ OPRK1 P41145 2/20 0.45
▸ GSR P00390 1/20 0.44
▸ NOD1 Q9Y239 1/20 0.42
▸ NTSR2 O95665 1/20 0.42
▸ NTSR1 P30989 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ SLC6A5 Q9Y345 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ CPB2 Q96IY4 1/20 0.41
▸ LAP3 P28838 2/20 0.41
▸ MMP2 P08253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27639948 1.00 TERT (0.50) TERTGNAI3GNAO1GNAI1ERAP2
SCHEMBL6534852 0.94 TERT (0.45) TERTGNAI3GNAO1GNAI1ERAP2
SCHEMBL6534849 0.94 TERT (0.45) TERTGNAI3GNAO1GNAI1ERAP2
SCHEMBL29987029 0.90 ERAP2 (0.55) TERTGNAI3GNAO1GNAI1ERAP2
SCHEMBL30537470 0.88 NMT2 (0.47) TERTERAP2ERAP1LNPEPOPRD1
SCHEMBL2887196 0.88 TERT (0.52) TERTGNAI3GNAO1GNAI1ERAP2
SCHEMBL2887200 0.88 TERT (0.52) TERTGNAI3GNAO1GNAI1ERAP2
SCHEMBL31433387 0.88 ERAP2 (0.53) TERTERAP2ERAP1LNPEPOPRD1
SCHEMBL8013829 0.86 GSR (0.51) GNAI3GNAO1GNAI1ERAP2ERAP1
SCHEMBL20818872 0.86 GSR (0.51) GNAI3GNAO1GNAI1ERAP2ERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661266-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES Elcelyx Therapeutics, Inc. (US) 2013-11-13 — — EP claimed
WO-2012094636-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — WO claimed
US-20240108040-A1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2024-04-04 — — US disclosed
US-11758933-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2023-09-19 — — US disclosed
EP-3368542-B1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2022-06-22 — — EP disclosed
US-11357246-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2022-06-14 — — US disclosed
US-20210227863-A1 HIGH INTENSITY SWEETENERS SENOMYX, INC. 2021-07-29 — — US disclosed
EP-3356356-B1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED (US) 2021-05-26 — — EP disclosed
EP-3763419-A1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES Anji Pharma (US) LLC (US) 2021-01-13 — — EP disclosed
EP-2661266-B1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ANJI PHARMA (US) LLC (US) 2020-09-16 — — EP disclosed
US-10610500-B2 Chemosensory receptor ligand-based therapies ANJI PHARMA (US) LLC (US) 2020-04-07 — — US disclosed
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — US disclosed
WO-2012094636-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — WO disclosed
WO-2012054528-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-04-26 — — WO disclosed
US-20110177545-A1 G-PROTEINS GIVAUDAN SA (CH) 2011-07-21 — — US disclosed
US-7919236-B2 G-proteins GIVAUDAN SA (CH) 2011-04-05 — — US disclosed
EP-1581555-B1 CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS GIVAUDAN SA (CH) 2008-04-30 — — EP disclosed
US-20060275765-A1 G-proteins GIVAUDAN SA (CH) 2006-12-07 — — US disclosed
EP-1581555-A2 G-PROTEINS Givaudan SA (CH) 2005-10-05 — — EP disclosed
WO-2004055048-A2 CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS GIVAUDAN SA (CH) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108040-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 TERT 3724/4885GNAI3 1684/4885GNAO1 1277/4885
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 TERT 2282/4885GNAI3 1028/4885GNAO1 603/4885
US-10610500-B2 Chemosensory receptor ligand-based therapies TAS1R2, TAS2R1, GPR119 TERT 2282/4885GNAI3 1028/4885GNAO1 603/4885
US-11357246-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 TERT 3724/4885GNAI3 1684/4885GNAO1 1277/4885
US-20210227863-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 TERT 3724/4885GNAI3 1684/4885GNAO1 1277/4885
US-11758933-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 TERT 3724/4885GNAI3 1684/4885GNAO1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.